

References

I-26

1. American Urological Association. Castration-resistant prostate cancer: AUA guideline.2023 Accessed May 9, 2023.
2. Scholz M, Yep S, Chancey M, et al. Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer. *ImmunoTargets*. 2017;11-16.
3. Micromedex DrugDex Compendium®. 2023.Sipuleucel-T.
4. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Sipuleucel-T.
5. Delaware State Mandate; 18 DE Code, §§3338B and 3555B.
6. Provenge (sipuleucel-T) suspension for intravenous infusion [package insert]. Dendreon Pharmaceuticals, LLC. Seal Beach, CA. Revised 07/2017.
7. National Comprehensive Cancer Network (NCCN). Sipuleucel-T. NCCN Drugs and Biologics Compendium® 2023.
8. McKay RR, Hafron JM, Ferro C, et al. A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer. *Adv Ther*. 2020;37(12):4910-4929.
9. Sartor O, Armstrong AJ, Ahaghotu C, et al. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. *Prostate Cancer Prostatic Dis*. 2020;23(3):517-526.